Prospective Study
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2015; 21(29): 8935-8942
Published online Aug 7, 2015. doi: 10.3748/wjg.v21.i29.8935
Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients
Arghavan Haj-sheykholeslami, Maryam Keshvari, Heidar Sharafi, Ali Pouryasin, Khalil Hemmati, Fatemeh Mohammadzadehparjikolaei
Arghavan Haj-sheykholeslami, Khalil Hemmati, Fatemeh Mohammadzadehparjikolaei, The Liver, Pancreatic, and Biliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran 14117-13135, Iran
Maryam Keshvari, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran 14665-1157, Iran
Heidar Sharafi, Middle East Liver Disease Center, Tehran 14155-3651, Iran
Heidar Sharafi, Ali Pouryasin, Armin Pathobiology Laboratory, Tehran 1235642351, Iran
Author contributions: Keshvari M and Pouryasin A designed the research; All patients were evaluated and treated by Keshvari M; Sharafi H and Pouryasin A performed the molecular assessments; Hemmati K and Mohammadzadehparjikolaei F extracted the data from the patients’ documents and completed the side effect questionnaires by interviewing the patients; Sharafi H performed the statistical analysis; and Haj-sheykholeslami A wrote the article and the final draft was reviewed by Keshvari M.
Supported by Pooyesh Darou which is the local manufacturer of pegylated interferon alpha-2a in Iran (Pegaferon).
Institutional review board statement: This study was approved by the Ethics Committee of the Iranian Blood Transfusion Organization. The study protocol conformed to the ethical guidelines of the 1975 declaration of Helsinki.
Informed consent statement: Informed consent was obtained from all patients participating in the study.
Conflict-of-interest statement: This study was financially supported by Pooyesh Darou, which is the local manufacturer of pegylated interferon alpha-2a in Iran (Pegaferon®). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Data sharing statement: Dataset is available from the corresponding author at
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Maryam Keshvari, MD, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran 14665-1157, Iran.
Telephone: +98-21-66592126 Fax: +98-21-66900386
Received: November 23, 2014
Peer-review started: November 24, 2014
First decision: December 11, 2014
Revised: February 10, 2015
Accepted: April 9, 2015
Article in press: April 9, 2015
Published online: August 7, 2015


AIM: To evaluate the efficacy of pegylated interferon in Iranian chronic hepatitis C patients in relation to interferon-λ (IFNL) polymorphisms.

METHODS: This study enrolled patients with chronic hepatitis C referred to the Tehran Blood Transfusion Hepatitis Clinic in 2011. Patients were included in the study if they had no concomitant hepatic illness, were negative for human immunodeficiency virus antibodies, and had no prior history of treatment with any type of pegylated interferon. Patients were treated with 180 μg pegylated interferon alpha-2a (Pegaferon®) weekly and 800-1200 mg ribavirin daily for 24 or 48 wk depending on weight and hepatitis C virus (HCV) genotype. Blood samples were collected from patients to obtain DNA for determination of IFNL rs12979860 and rs8099917 polymorphisms. The virologic response in patients was then evaluated and compared between the different IFNL genotypes.

RESULTS: A total of 152 patients with a mean age of 41.9 ± 10.0 years were included in the study, of which 141/152 were men (92.8%). The most frequent HCV genotype was type-1, infecting 93/152 (61.2%) patients. Sustained virologic response (SVR) was achieved in 81.9% of patients with HCV genotype-1 and 91.1% of patients with HCV genotype-3. Treatment success was achieved in 91.2% (52/57) of patients with the IFNL rs12979860 CC genotype and 82.1% (78/95) in those with other genotypes. Similar treatment response rates were also observed in patients with rs8099917 TT (39/45; 86.7%) and non-TT (61/68; 89.7%) genotypes. Univariate analyses identified the following factors which influenced treatment response for inclusion in a multivariate analysis: age, HCV RNA level, stage of liver fibrosis, rs12979860 CC genotype, and aspartate transaminase level. A logistic regression analysis revealed that only the rs12979860 CC genotype was significantly associated with achievement of SVR (OR = 6.2; 95%CI: 1.2-31.9; P = 0.03).

CONCLUSION: The rs12979860 CC genotype was associated with SVR in patients receiving pegylated interferon plus ribavirin, however, the SVR rate in other rs12979860 genotypes was also relatively high.

Key Words: Chronic hepatitis C, Pegylated interferon, rs12979860, rs8099917, Sustained virologic response

Core tip: Chronic hepatitis C-infected Iranian patients treated with pegylated interferon and ribavirin showed relatively high rates of sustained virologic response. Treatment success was not influenced by hepatitis C virus genotype. However, a comparison of treatment success related to IFNL polymorphisms (also known as IL28B polymorphisms) using a logistic regression analysis revealed that the interferon-λ rs12979860 CC genotype was significantly associated with achieving a sustained virologic response.


Chronic infection with the hepatitis C virus (HCV) is a serious condition that can lead to cirrhosis or hepatocellular carcinoma. An estimated 150 million people worldwide are chronically infected with HCV, which is responsible for 350000 liver-related deaths annually[1]. In Iran, the prevalence of chronic HCV infection is approximately 0.5%[2]. With the advent of new potent drugs such as direct acting oral agents, recommendations for chronic hepatitis C treatment in adults is rapidly changing. Although these new agents are more effective and have fewer side effects they are offered at very high prices, making pegylated interferon (Peg-IFN) plus ribavirin the only affordable treatment option for a large group of patients, especially those in developing countries[3]. Until recently the Peg-IFN regimen was the mainstay of chronic hepatitis C treatment, and resulted in a sustained virologic response (SVR) in 33%-80% of patients[4,5]. However, data regarding the response rate of Iranian patients to Peg-IFN is limited, with the reported success rates ranging from 50%[6] to 61%[7]; although these studies were not restricted to the evaluation of treatment-naïve patients.

Treatment outcome can be affected by various factors, including single nucleotide polymorphisms (SNPs) of interferon-λ (IFNL) (located near the IL28B gene and thus also known as IL28B polymorphisms) such as rs12979860 and rs8099917[8]. These SNPs are also associated with spontaneous clearance of HCV[9,10]. Studies have shown that rs12979860 “CC” and rs8099917 “TT” genotypes are significantly associated with preferred treatment outcome[11,12]. Thus, to further investigate the role of these SNPs, the success of Peg-IFN-alpha-2a plus ribavirin treatment in Iranian patients with chronic HCV infection was evaluated with respect to host genetics and HCV genotypes.

Study population

Adult patients with chronic HCV infection (defined as the presence of HCV RNA in serum for > 6 mo) referred to the Tehran Blood Transfusion Hepatitis Clinic between March 2011 and August 2013 were enrolled in the study. Patients with no concomitant hepatic illness, negative results for human immunodeficiency virus antibody and hepatitis B surface antigen, and no history of prior antiviral therapy for HCV infection were included in the study. A majority of the patients underwent percutaneous liver biopsy, for which specimens were evaluated according to the modified Knodell score grading and staging system by Ishak et al[13].

Treatment regimen

Patients received weekly subcutaneous injections of Peg-IFN-alpha-2a (180 μg/mL Pegaferon®; Pooyesh Darou, Tehran, Iran) and daily oral ribavirin (Ribabiovir®; Bakhtar Bioshimi, Kermanshah, Iran): 800 mg for HCV genotype-3 and 1000-1200 mg according to the patient’s weight (< or ≥ 75 kg) for HCV genotype-1.

Treatment duration was 24 wk for those infected with HCV genotype-3, or 48 wk for infection with HCV genotype-1, but could be shortened or extended depending on the patient’s response and compliance.

The patients were closely monitored throughout the treatment course, with monthly complete blood cell count and liver enzyme tests, and HCV RNA level assessment before treatment, at weeks 4, 12, 24, at the end of treatment, and 24 wk after treatment completion. Informed consent was obtained from all participating patients. The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the Ethics Committee of the Iranian Blood Transfusion Organization.

Laboratory assessments

Quantitative assessment of HCV RNA was performed using the COBAS TaqMan HCV Test v2.0 (Roche Diagnostics, Basel, Switzerland) according to the manufacturer’s instructions and a detection limit of 10 IU/mL. HCV genotyping was performed using HCV genotype-specific primers[14].

The IFNL SNPs were assessed using the PCR-restriction fragment length polymorphism method[15]. Briefly, genomic DNA was extracted from patients’ peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The PCR was performed using Accupower PCR PreMix (Bioneer Corp., Daejeon, South Korea) with the following conditions: 94 °C for 5 min, 35 cycles of 94 °C for 20 s, 66 °C for 20 s, and 72 °C for 20 s, followed by 72 °C for 5 min. Primers used for the reaction included: rs12979860, 5’-GCGGAAGGAGCAGTTGCGCT-3’ and 5’-GGGGCTTTGCTGGGGGAGTG-3’; or rs8099917, 5’-CCCACTTCTGGAACAAATCGTCCC-3’ and 5’-TCTCCTCCCCAAGTCAGGCAACC-3’. The PCR amplicons were then digested for ≥ 1 h with 10 U of restriction endonuclease: BstUI for rs12979860 or BsrDI for rs8099917 (Fermentas of Thermo Fisher Scientific, Waltham, MA, United States). The digested PCR products were separated on 3% agarose gels revealing the following sized fragments: rs12979860, 196 and 45 bp for the CC genotype, 241, 196, and 45 bp for the CT genotype, or 241 bp for the TT genotype; rs8099917, 552 bp for the TT genotype, 552, 322 and 230 bp for the GT genotype, and 322 and 230 bp for the GG genotype.

Assessment of treatment response

Therapeutic responses were categorized as: rapid virologic response (RVR; HCV RNA undetectable after 4 wk of treatment), early virologic response (EVR; HCV RNA undetectable or ≥ 2 log decreased at 12th wk of treatment), or sustained virologic response (SVR; HCV RNA undetectable at 6 mo after the end of treatment). Achievement of SVR was considered as treatment success, and thus used to describe patients as responders or non-responders. HCV breakthrough was used to describe cases where HCV RNA was detected during treatment after a previous period where it was undetectable, and resistant infections were cases where HCV RNA was detectable at all times. If HCV RNA was undetectable at the end of therapy, but then detected 6 mo later, this was considered a relapse[16].

Statistical analysis

Statistical analyses were performed using SPSS v16.0 software (SPSS Inc., Chicago, IL, United States). The association of each nominal variable with SVR achievement was evaluated with cross tabulation and χ2 testing. Independent sample Student’s t tests were used for continuous variables with a normal distribution, otherwise the Mann-Whitney U test was used. All baseline variables that had a P < 0.2 in univariate tests were entered into a logistic regression model, and P < 0.05 was considered statistically significant. The statistical methods used in this study were reviewed by Maryam Sharafkhah, MS, of the Biostatistics in Digestive Diseases Research Institute.

Patient characteristics

A total of 152 patients (141 men and 11 women; mean age 41.9 ± 10.0 years) with chronic HCV infection were included in this study. The mean HCV RNA level was 3920258 ± 6856760 IU/mL (interquartile range: 4420288 IU/mL). A larger proportion of patients (93/152; 61.2%) were infected with HCV genotype-1 (1a: n = 86; 1b: n = 7), and the remaining patients were infected with HCV genotype-3a (n = 56), a mixed genotype-1a/3a (n = 2), or mixed genotype-1a/4 (n = 1).

The frequencies of IFNL rs12979860 CC, CT, and TT genotypes were 37.5%, 47.3%, and 13.2%, respectively, and were 60.2%, 37.2%, and 2.7% for rs8099917 TT, GT, and GG genotypes, respectively. There were no significant differences in rs12979860 and rs8099917 subtype frequencies with respect to HCV genotype.

Liver biopsies were performed in 99/152 (65.1%) patients, indicating stage 0 (n = 8), stage 1 (n = 23), stage 2 (n = 26), stage 3 (n = 27), or stage 4 (n = 4) fibrosis, or cirrhosis (n = 11).

Treatment response

Treatment duration was reduced to < 48 wk for 24/94 (25.5%) patients with HCV genotype-1 infection (15 with shortened treatment course, two as a result of non-compliance, and seven following treatment failure), and to < 24 wk in one non-compliant HCV genotype-3 subject. Treatment was prolonged up to 72 wk in 14/94 (14.9%) patients with HCV genotype-1 infection because of cirrhosis or the continued presence of HCV RNA at 12 wk. Similarly, 10 patients with HCV genotype-3 infection required an extended 48-wk therapy course. Treatment course was withdrawn in 1 subject due to attempted suicide. The 11 patients with cirrhosis did not show signs of ascites or thrombocytopenia, and treatment was therefore administered.

The treatment outcomes for all patients and according to HCV genotypes are shown in Table 1. Although the rates of EVR and SVR did not differ between the HCV genotype-1 and genotype-3 groups, the rate of RVR was significantly higher in patients with HCV genotype-3 than in patients with HCV genotype-1 (P < 0.01). Furthermore, 44/62 (71.0%) patients who did not demonstrate RVR and 7/14 (50.0%) patients who did not show EVR eventually achieved SVR. Therefore, overall, RVR and EVR were significantly related to treatment success (P < 0.01).

Table 1 Treatment outcomes n (%).
Hepatitis C virus genotypeVirologic response
RapidEarlyEnd of treatmentSustained
Type-11 (n = 94)42 (44.7)86 (91.5)85 (90.4)77 (81.9)6 (6.4)3 (3.2)8 (8.5)
Type-3 (n = 56)47 (83.9)b49 (89.1)256 (100)51 (91.1)0 (0)0 (0)5 (8.9)
Mixed type-1 and -3 (n = 2)1 (50.0)2 (100)2 (100)2 (100)0 (0)0 (0)0 (0)
Total (n = 152)90 (59.2)137 (90.7)2143 (94.1)130 (85.5)6 (3.9)3 (2.0)13 (8.6)
Predictors of treatment response

The age, baseline HCV RNA level, liver fibrosis stage, serum alanine and aspartate transaminase levels, and body mass index were compared among treatment responders and non-responders within the HCV genotype groups (Table 2). Patients with mixed HCV genotypes were excluded from analyses due to the small sample size. The baseline characteristics did not differ between HCV genotype groups, although responders were significantly younger (P < 0.01), and had lower HCV RNA levels (P = 0.04) than non-responders. These differences were not significant within the HCV genotype subgroups. In contrast, body mass index did not differ within the entire cohort with regard to treatment response, however, responders with HCV genotype-1 infection had a significantly higher body mass index than non-responders (P = 0.03).

Table 2 Baseline variables according to treatment response.
VariableAll subjects
HCV genotype-1
HCV genotype-3
R(n = 130)NR(n = 22)R(n = 77)NR(n = 17)R(n = 51)NR(n = 5)
Age (yr)40.9 ± 9.4a47.7 ± 11.541.7 ± 9.047.9 ± 11.940.0 ± 10.146.8 ± 8.9
HCV RNA (× 105 IU/mL)35.6 ± 55a60.1 ± 99.537.9 ± 48.670.1 ± 111.632.4 ± 64.926.3 ± 16.8
Liver fibrosis stage2.2 ± 1.53.0 ± 1.72.3 ± 1.53.0 ± 1.81.8 ± 1.33.0 ± 0.0
ALT (IU/L)71.9 ± 57.7100.9 ± 108.774.2 ± 63.977.9 ± 63.770.1 ± 47.9198.7 ± 203.6
AST (IU/L)44.5 ± 26.471.2 ± 66.844.9 ± 28.758.5 ± 47.644.4 ± 23.3125.2 ± 113.5
BMI (kg/m2)26.9 ± 4.025.8 ± 3.427.2 ± 3.5a25.1 ± 3.026.2 ± 4.629.5 ± 3.7

Table 3 shows the prevalence of rs12979860 and rs8099917 genotypes with respect to treatment response. Among subjects with rs12979860 CC genotype, 91.2% (52/57) responded successfully to treatment, whereas 82.1% (78/95) of patients with a non-CC genotype responded. Treatment success occurred in 86.7% (39/45) of patients with the rs8099917 TT genotype, and in 89.7% (61/68) of those with a non-TT genotype. Univariate analyses revealed that there were no differences in the prevalence of the IFNL genotypes between responders and non-responders for either polymorphism. However, among patients with HCV genotype-1 infection, the rs12979860 CC genotype was significantly related to treatment success (94.1% vs 75.0%; P = 0.02). This was not observed in the HCV genotype-3 group.

Table 3 Prevalence of single nucleotide polymorphisms n (%).
Hepatitis C virus genotypers12979860 genotype
rs8099917 genotype1
Responders32 (41.6)45 (58.4)32 (59.3)22 (40.7)
Non-responders2 (11.8)15 (88.2)3 (33.3)6 (66.7)
Responders20 (39.2)31 (60.8)28 (63.6)16 (36.4)
Non-responders3 (60.0)2 (40.0)4 (100)0 (0)
Mixed type-1 and -3
Responders0 (0)2 (100)1 (50.0)1 (50.0)
Non-responders0 (0)0 (0)0 (0)0 (0)
Responders52 (40.0)78 (60.0)39 (39.0)61 (61.0)
Non-responders5 (22.7)17 (77.3)7 (53.8)6 (46.2)

Patients with the rs12979860 CC genotype had significantly higher HCV RNA levels compared to those with a non-CC genotype (60.9 × 105± 81.8 × 105 IU/mL vs 26.4 × 105± 45.7 × 105 IU/mL, P = 0.01). Further analyses also revealed that RNA levels of HCV genotype-1 were significantly higher in patients with rs12979860 CC vs other genotypes (71.6 × 105± 88.1 × 105 IU/mL vs 28 × 105± 40.2 × 105 IU/mL, P < 0.01). However, this was not the case for patients in the HCV genotype-3 group. In addition rs12979860 CC and rs8099917 TT genotypes were significantly related to achievement of RVR (both P < 0.05), but not EVR. RVR was also significantly associated with rs12979860 CC and rs8099917 TT genotypes in patients infected with HCV genotype-1 (P = 0.01).

Logistic regression analysis of treatment success was conducted according to age, categorical HCV RNA level, stage of liver fibrosis, rs12979860 CC genotype, and aspartate transaminase level (variables identified by P < 0.2 in univariate analyses). The results showed that only rs12979860 CC genotype was a predictor of SVR achievement (P = 0.03). Table 4 shows the results of multivariate analysis.

Table 4 Predictive factors of treatment success.
Baseline variableP valueOdds ratio95%CI
HCV RNA level (categorical)0.300.530.16-1.75
Stage of liver fibrosis0.220.770.50-1.17
rs12979860 CC genotype0.0316.231.22-31.88

A wide range of response rates has been reported for Peg-IFN and ribavirin treatment of chronic HCV infection, reflecting the various settings and patient selections. For example, these values range from 7% in patients with HCV genotype-1 and high viral load[17] to 80% in patients with HCV genotype-2 and -3[5,18]. Although recently more effective treatments for chronic hepatitis C have been introduced, the high cost of these treatments has made the Peg-IFN plus ribavirin regimen the only affordable treatment option in many developing countries[3]. Jabbari et al[19] reported a high success rate with this regimen in Iranian patients with HCV genotype-3 compared to genotype-1 (95% vs 67%), and another Iranian study reported an 83.8% success rate in patients with HCV genotype-3 and 72.6% in those with HCV genotype-1[20]. Moreover, Alavi Moghaddam et al[21] reported an excellent treatment success rate of 95.6% in 45 younger hemophiliac patients (mean age 30.4 ± 12.6 years) with HCV genotypes-1 and -3. The results from these Iranian studies are in line with our results presented herein. Studies on the success rate of this treatment regimen in neighboring countries are rare and comparing the results of the existing ones is also difficult due to different HCV genotype distributions. A study from Turkey reported SVR rates of 48.6% and 35.1% in a group of patients with HCV genotype-1 treated with Peg-IFN-alpha-2a or Peg-IFN-alpha-2b, respectively[22].

A report by Muir et al[23] found that responses to Peg-IFN varied among ethnicities regardless of the HCV genotype, with the lowest rates (22%) in African Americans, and the highest (59%) in Asian Americans. Another study reported an SVR rate of 76% in Asian patients vs 36% in Caucasians[24]. Thus, ethnic differences may explain the higher success rates in the Iranian patients reported here and elsewhere[21].

Another interesting finding in our study was the same treatment success rate in HCV genotype- 1 and -3 patients. Lin et al[25] showed that patients younger than 40 with HCV genotype-1 had a treatment response similar to HCV genotype-2 infection. Moreover, a study by Gheorghe et al[26] showed that patients with HCV genotype-1 and mild hepatitis had a high rate of SVR similar to those with other HCV genotypes, young age and low level of viremia and significant hepatocytolisis were found to be independent predictors of SVR. These findings can explain the similar SVR achievement rates between the 2 HCV genotype groups in our study regardless of IFNL polymorphism. It is also possible that apart from ethnic differences, the relatively younger age of the participants and their high compliance (3.6% dropout rate) in our study accompanied by the fact that we only included treatment-naïve patients contributed to the observed high treatment success rate.

The identification of rs12979860 and rs8099917 genotypes has been recommended prior to treatment of patients infected with HCV genotype-1 or -4 due to the possibility of a more favorable outcome[8]. Although a meta-analysis performed by Belgian scientists demonstrated that favorable IL28B genotypes are associated with higher RVR and SVR rates in HCV genotype-2 and -3 patients, but as their impact on SVR was slim, they did not recommend IL28B genotyping before therapeutic interventions in these patients[11]. The findings reported herein indicate that only the rs12979860 CC genotype significantly affects SVR, which is consistent with another previous Iranian study on 48 patients infected with HCV genotype-1, where the SVR rate was higher in those with the rs12979860 CC genotype in comparison to those with rs12979860 TT genotype[27]. Nevertheless, in the present study, both rs12979860 and rs8099917 were related to RVR, but not EVR achievement, regardless of HCV genotype. The distributions of rs12979860 and rs8099917 SNPs observed in this study were concordant with previous reports[28,29].

As we only included 152 subjects in our study and had a high treatment success rate, only 22 patients failed to achieve SVR, therefore a larger sample size with more subjects in the non-responder group may have confirmed these results with more certainty. Although in this study reaching RVR and EVR were both significantly related to treatment success, SVR was still achieved in more than half of the patients that initially had failed to reach RVR or EVR (71% and 50%, respectively).

The results of the present study also show that patients with the rs12979860 CC genotype had more than two times the HCV RNA level than non-CC genotypes, which has been reported for various HCV genotypes throughout the various courses of infection (acute, early chronic, and chronic)[30-33]. Bucci et al[34] reported similar results in 201 HCV genotype-3 patients from the United Kingdom, this study showed that favorable IL28B polymorphisms (rs8099917) are associated with a marked increase in baseline viral load and RVR achievement, but not SVR. Domagalski et al[32] also confirmed the association between favorable rs12979860 CC genotype and higher baseline viral loads in patients with HCV genotype 1 and 4. Abe et al[35] reported more severe inflammation and fibrosis in the homozygous bearers of major IL28B alleles questioning their benefit outside the treatment context. It is suggested that different IL28B polymorphisms induce different cytokine profiles that can cause different inflammatory or biochemical results in the course of chronic HCV infection. This apparent paradox between higher baseline HCV RNA level, which has been linked to treatment failure in many studies[36,37], and higher response rate in patients with the rs12979860 CC genotype requires further investigation.

More large scale multi-centric studies are needed to reliably evaluate the response rate of patients in different ethnical or geographical parts of the world and to identify the responsible factors for high success rates in specific populations to improve the treatment outcome for all patients with chronic hepatitis C.

In conclusion, this study shows that the SVR achievement rate is high in Iranian treatment-naïve patients regardless of HCV genotype. Although the rs12979860 CC genotype showed a strong relationship with SVR achievement, the comparatively high level of SVR achievement with Peg-IFN and ribavirin in patients with other rs12979860 genotypes indicates that the Iranian patient’s IFNL polymorphism should not alter treatment decisions.


Chronic hepatitis C virus (HCV) infection is a major public health problem that can result in cirrhosis and lead to hepatocellular carcinoma or even death. For the past decade, Pegylated interferon (Peg-IFN) has been the primary therapeutic intervention for chronic HCV infection, although its efficacy is influenced by many factors, including single nucleotide polymorphisms in or near the IL28B gene.

Research frontiers

Many studies have reported wide ranging efficacies for Peg-IFN and ribavirin in the treatment of chronic HCV infection. Although patient age, viral load, and ethnicity can substantially affect treatment success, the role of host genetic factors, such as single nucleotide polymorphisms in relevant genes, are becoming more apparent. Thus, further understanding of the influence of these factors will help improve patient outcome.

Innovations and breakthroughs

The high response rate to Peg-IFN and ribavirin is an important finding of this study, and may support the decision to accept treatment by many patients with chronic HCV infection, particularly those in developing countries. The high response rate of Iranian patients to Peg-IFN and ribavirin in this study highlights that the conventional dual therapy can still be considered the first-line treatment for these patients.


The results of this study show that the rs12979860 CC genotype is a strong predictor of treatment response. Thus, patients with this rs12979860 genotype can achieve greater benefit from Peg-IFN and ribavirin treatment.


Interferon-λ is a cytokine that is involved in host defense against viral infections, such as hepatitis C. Single nucleotide polymorphisms are genetic variations within the DNA that are common within a population.


The authors carried out a cross-sectional multivariate analysis to describe positive predictive factors for response to HCV treatment with Peg-IFN alpha-2a plus ribavirin in a naïve Iranian cohort. Special attention is given to IL28B polymorphisms as a target to predict sustained viral response. They observed a similar finding to previous reports showing a relationship between the IFNL rs12979860 CC genotype and a higher sustained virologic response probability. The patient cohort demonstrated a high sustained virologic response rate overall, which could be related to ethnic factors that render the Iranian population more sensitive to Peg-IFN plus ribavirin treatment.


P- Reviewer: Grassi A, Larrubia JR, Said ZNA S- Editor: Ma YJ L- Editor: Webster JR E- Editor: Wang CH

1.  World Health Organization. Hepatitis C: World Health Organization 2015; .  [PubMed]  [DOI]
2.  Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, Zaer-rezaii H, Amini-Kafiabad S, Maghsudlu M, Pourshams A. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010;14 Suppl 3:e113-e116.  [PubMed]  [DOI]
3.  Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014;58:928-936.  [PubMed]  [DOI]
4.  Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.  [PubMed]  [DOI]
5.  Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.  [PubMed]  [DOI]
6.  Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012;12:e6151.  [PubMed]  [DOI]
7.  Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, Lankarani KB. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010;30:1173-1180.  [PubMed]  [DOI]
8.  Jia Z, Ding Y, Tian S, Niu J, Jiang J. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. PLoS One. 2012;7:e45698.  [PubMed]  [DOI]
9.  Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M. The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon. 2014;14:e22649.  [PubMed]  [DOI]
10.  Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52:1216-1224.  [PubMed]  [DOI]
11.  Schreiber J, Moreno C, Garcia BG, Louvet A, Trepo E, Henrion J, Thabut D, Mathurin P, Deltenre P. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Aliment Pharmacol Ther. 2012;36:353-362.  [PubMed]  [DOI]
12.  Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013;11:6.  [PubMed]  [DOI]
13.  Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.  [PubMed]  [DOI]
14.  Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JY. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35:201-207.  [PubMed]  [DOI]
15.  Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, Salimi S, Kheradvar O. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. Hepat Mon. 2012;12:190-195.  [PubMed]  [DOI]
16.  European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61:373-395.  [PubMed]  [DOI]
17.  Sharieff KA, Duncan D, Younossi Z. Advances in treatment of chronic hepatitis C: ‘pegylated’ interferons. Cleve Clin J Med. 2002;69:155-159.  [PubMed]  [DOI]
18.  Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2004;8:iii-iv, 1-125.  [PubMed]  [DOI]
19.  Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, Zamini H, Shahzamani K, Merat S, Nassiri-Toosi M. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med. 2010;13:306-312.  [PubMed]  [DOI]
20.  Jabbari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K, Zamini H, Merat S, Malekzadeh R, Sharfi AH. Pegaferon in hepatitis C: Results of a Multicenter Study. Middle East J Dig Dis. 2011;3:110-114.  [PubMed]  [DOI]
21.  Alavi Moghaddam M, Zali MR, Aalaei Andabili SH, Derakhshan F, Miri SM, Alavian SM. High Rate of Virological Response to Peginterferon α-2a-Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C. Iran Red Crescent Med J. 2012;14:466-469.  [PubMed]  [DOI]
22.  Yenice N, Mehtap O, Gümrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol. 2006;17:94-98.  [PubMed]  [DOI]
23.  Muir AJ, Hu KQ, Gordon SC, Koury K, Boparai N, Noviello S, Albrecht JK, Sulkowski MS, McCone J. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat. 2011;18:e134-e143.  [PubMed]  [DOI]
24.  Yan KK, Guirgis M, Dinh T, George J, Dev A, Lee A, Zekry A. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2008;14:3416-3420.  [PubMed]  [DOI]
25.  Lin CY, Sheen IS, Jeng WJ, Huang CW, Huang CH, Chen JY. Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism. Ann Hepatol. 2013;12:62-69.  [PubMed]  [DOI]
26.  Gheorghe L, Iacob S, Grigorescu M, Sporea I, Sirli R, Damian D, Gheorghe C, Iacob R. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C. J Gastrointestin Liver Dis. 2009;18:51-56.  [PubMed]  [DOI]
27.  Rashidi RNTM, Shah Siya R, Forutan H, Merat SH, Ebrahimi Daryani N. The Effect of Interleukin 28 B Polymorphism on Sustained Virology Response (SVR) in Patients with Chronic Hepatitis C. Govaresh. 2010;15.  [PubMed]  [DOI]
28.  Keshvari M, Pouryasin A, Behnava B, Sharafi H, Hajarizadeh B, Alavian SM. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014;39:343.  [PubMed]  [DOI]
29.  Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, Mehrnoush L, Fatemi A. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012;12:e8387.  [PubMed]  [DOI]
30.  Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M. Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol. 2014;61:430-434.  [PubMed]  [DOI]
31.  Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; the InC3 Study Group. Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC(3) study. J Viral Hepat. 2015;22:708-717.  [PubMed]  [DOI]
32.  Domagalski K, Pawlowska M, Tretyn A, Halota W, Tyczyno M, Kozielewicz D, Dybowska D. Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4. Hepat Mon. 2013;13:e13678.  [PubMed]  [DOI]
33.  Ydreborg M, Westin J, Rembeck K, Lindh M, Norrgren H, Holmberg A, Wejstål R, Norkrans G, Cardell K, Weiland O. Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS One. 2013;8:e80172.  [PubMed]  [DOI]
34.  Bucci C, von Delft A, Christian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W. ‘Favourable’ IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. J Gen Virol. 2013;94:1259-1265.  [PubMed]  [DOI]
35.  Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439-443.  [PubMed]  [DOI]
36.  Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz I, Głowacki MK, Owczarek D, Cibor D, Sanak M, Mach T. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. World J Gastroenterol. 2012;18:4892-4897.  [PubMed]  [DOI]
37.  Ladero JM, Martin EG, Fernández C, Carballo M, Devesa MJ, Martínez C, Suárez A, Díaz-Rubio M, Agúndez JA. Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data. J Gastroenterol Hepatol. 2012;27:279-285.  [PubMed]  [DOI]